Verificando…
Traduzido automaticamente. Doses e advertências: confira o original em inglês. Ler em inglês
Início / Registado na Nigéria / Cefpodoxime Proxetil Sandoz Tablet

Cefpodoxime Proxetil Sandoz Tablet

NAFDAC Reg. No. C4-1626 · Drug

Registered with NAFDAC. Registration activeAs of 30 October 2026 · synced automatically from official sources.
Product
Cefpodoxime Proxetil Sandoz Tablet
Número NAFDAC
C4-1626
Princípio ativo
Cefpodoxime (Cefpodoxime Proxetil)
Dosagem
200 mg
Forma
Tablet
Tamanho da embalagem
1 x 10's (in blister)
Manufacturer
Not listed
Applicant (holder)
Novartis Nigeria Limited
Approved
25 Feb 2021
Situação
Inactive View on NAFDAC ↗
Registro válido até
24 Feb 2026
Alertas da OMS
None found
Community reports
None
Times checked
0

About the medicine: Cefpodoxime: uses, dosage and brands worldwide

What we found

  • Cefpodoxime Proxetil Sandoz Tablet is on the NAFDAC register with an active registration (C4-1626). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Cefpodoxime Proxetil Sandoz Tablet

O que diz a bula oficial. Se um médico receitou, siga a receita. Se a bula da sua caixa for diferente, vale a da sua caixa.

Para quem é

Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). …

Como tomar e com que frequência

(See INDICATIONS AND USAGE for indicated pathogens.) Film-coated Tablets Cefpodoxime Proxetil Tablets, USP should be administered orally with food to enhance absorption. ( See CLINICAL PHARMACOLOGY .) The recommended dosages, durations of treatment, and applicable patient population are as described in the following chart: Adults and Adolescents (age 12 years and older) Type of Infection Total Daily Dose Dose Frequency Duration Pharyngitis and/or tonsillitis 200 mg 100 mg Q 12 hours 5 to 10 days Acute community acquired - pneumonia 400 mg 200 mg Q 12 hours 14 days Acute bacterial exacerbations of chronic bronchitis 400 mg 200 mg Q 12 hours 10 days Uncomplicated gonorrhea (men and women) and rectal gonococcal infections (women) 200 mg single dose Skin and skin structure 800 mg 400 mg Q 12 hours 7 to 14 days Acute maxillary sinusitis 400 mg 200 mg Q 12 hours 10 days Uncomplicated urinary tract infection 200 mg 100 mg Q 12 hours 7 days Patients with Renal Dysfunction For patients with severe renal impairment (

Children

Safety and efficacy in infants less than 2 months of age have not been established.

Older adults

Of the 3338 patients in multiple-dose clinical studies of cefpodoxime proxetil film-coated tablets, 521 (16%) were 65 and over, while 214 (6%) were 75 and over. No overall differences in effectiveness or safety were observed between the elderly and younger patients. …

While you are taking it
  • Patients should be counseled that antibacterial drugs including cefpodoxime proxetil tablets, USP should only be used to treat bacterial infections
  • They do not treat viral infections (e.g., the common cold)
  • When cefpodoxime proxetil tablets, USP is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. …
Talk to a doctor first if

Cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.

Medicines it may not mix with

Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. …

Warnings

BEFORE THERAPY WITH CEFPODOXIME PROXETIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFPODOXIME, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFPODOXIME PROXETIL OCCURS, DISCONTINUE THE DRUG. …

Possíveis efeitos colaterais

Clinical Trials Film-coated Tablets (Multiple dose) In clinical trials using multiple doses of cefpodoxime proxetil film-coated tablets, 4696 patients were treated with the recommended dosages of cefpodoxime (100 to 400 mg Q 12 hours). There were no deaths or permanent disabilities thought related to drug toxicity. One-hundred twenty-nine (2.7%) patients discontinued medication due to adverse events thought possibly or probably related to drug toxicity. Ninety-three (52%) of the 178 patients who discontinued therapy (whether thought related to drug therapy or not) did so because of gastrointestinal disturbances, nausea, vomiting, or diarrhea. …

Pregnancy and breastfeeding

Pregnancy Teratogenic Effects Pregnancy Category B Cefpodoxime proxetil was neither teratogenic nor embryocidal when administered to rats during organogenesis at doses up to 100 mg/kg/day (2 times the human dose based on mg/m2) or to rabbits at doses up to 30 mg/kg/day (1 to 2 times the human dose based on mg/m2). There are, however, no adequate and well-controlled studies of cefpodoxime proxetil use in pregnant women. …

If you take too much

In acute rodent toxicity studies, a single 5 g/kg oral dose produced no adverse effects. In the event of serious toxic reaction from overdosage, hemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised. The toxic symptoms following an overdose of beta-lactam antibiotics may include nausea, vomiting, epigastric distress, and diarrhea.

Se esquecer uma dose

Tome assim que lembrar, a menos que esteja quase na hora da próxima dose. Nesse caso, pule a dose esquecida. Nunca tome duas doses de uma vez para compensar. Confira a bula, pois alguns medicamentos são diferentes.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2024-06-19.

Label for cefpodoxime (cefpodoxime proxetil), the active ingredient registered with NAFDAC.

Check your pack of Cefpodoxime Proxetil Sandoz Tablet

Add the expiry date on your pack for a full Trust Score.

Ou tire fotos da caixa
Restam 3 verificações grátis hoje Fontes oficiais: FDA dos EUA · EMA (UE) · NAFDAC · alertas da OMS

About Cefpodoxime Proxetil Sandoz Tablet

What is in Cefpodoxime Proxetil Sandoz Tablet?

Cefpodoxime Proxetil Sandoz Tablet contains Cefpodoxime (Cefpodoxime Proxetil) (200 mg), as tablet, according to its NAFDAC registration record.

Is Cefpodoxime Proxetil Sandoz Tablet registered with NAFDAC?

Yes. Cefpodoxime Proxetil Sandoz Tablet is listed on the NAFDAC register under registration number C4-1626, and its registration is active as of 30 October 2026.

Has Cefpodoxime Proxetil Sandoz Tablet been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Cefpodoxime Proxetil Sandoz Tablet in our automatically synced alert list.

How can I check that my pack of Cefpodoxime Proxetil Sandoz Tablet is genuine?

Run a free authenticity scan with the NAFDAC number C4-1626, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Cefpodoxime Proxetil Sandoz Tablet?

Follow your prescription or the leaflet in your pack. The official label says: (See INDICATIONS AND USAGE for indicated pathogens.) Film-coated Tablets Cefpodoxime Proxetil Tablets, USP should be administered orally with food to enhance absorption. ( See CLINICAL PHARMACOLOGY .) The recommended dosages, durations of treatment, and applicable patient population are as described in the following chart: Adults and Adolescents (age 12 years and older) Type of…

What is Cefpodoxime Proxetil Sandoz Tablet used for?

Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Strep (Summarised from the official U.S. FDA label for cefpodoxime (cefpodoxime proxetil). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Cefpodoxime Proxetil Sandoz Tablet? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.